Theravance Biopharma
- Country
- Ownership
- -
- Employees
- 99
- Market Cap
- -
- Introduction
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 36
- Registration Number
- NCT03555617
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Drug-Drug Interaction (DDI) Study for TD-9855
Phase 1
Completed
- Conditions
- Drug Drug Interaction (DDI)
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 41
- Registration Number
- NCT03432793
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Bowel Diseases, InflammatoryIntestinal Disorders
- Interventions
- Drug: TD-1473 oral capsuleDrug: [14C]-TD-1473 Oral CapsuleDrug: [14C]-TD-1473 IV bolus
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 20
- Registration Number
- NCT03408470
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
Phase 1
Completed
- Conditions
- Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
- Interventions
- Drug: TD-3504Drug: PlaceboDrug: 15N2-tofacitinib
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 32
- Registration Number
- NCT03103412
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects
Phase 1
Completed
- Conditions
- Healthy Adults, Elderly Subjects
- Interventions
- Drug: PlaceboDrug: TD-1439
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 40
- Registration Number
- NCT02954263
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Single Ascending Dose Study of TD-1439 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: PlaceboDrug: TD-1439
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 66
- Registration Number
- NCT02903095
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
TD-1473 for Active Ulcerative Colitis (UC)
Phase 1
Completed
- Conditions
- Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
- Interventions
- Drug: PlaceboDrug: TD-1473
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 40
- Registration Number
- NCT02818686
- Locations
- 🇷🇴
Theravance Biopharma Investigational Site, Bucharest, Romania
Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects
Phase 1
Completed
- Conditions
- Healthy Adults, Elderly Subjects
- Interventions
- Drug: TD-0714Drug: Placebo
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 50
- Registration Number
- NCT02709928
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Phase 2
Completed
- Conditions
- Multiple System Atrophy (MSA) With Orthostatic HypotensionPure Autonomic FailureParkinson Disease With Orthostatic HypotensionHypotension, OrthostaticParkinson DiseaseOrthostatic HypotensionNeurogenic Orthostatic HypotensionPure Autonomic Failure With Orthostatic Hypotension
- Interventions
- Drug: TD-9855Drug: Placebo
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 34
- Registration Number
- NCT02705755
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Dallas, Texas, United States
A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: [14C]-GSK961081 solution for IV infusionDrug: [14C]-GSK961081 oral solutionDrug: GSK961081 dry powder for inhalation
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 6
- Registration Number
- NCT02663089
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath